Fed Circuit affirms GSK $107m patent loss
20-11-2020
Sandoz secures victory against GSK in passing off case
08-10-2019
GSK ordered to pay Vectura $89.7m in patent damages
07-05-2019
16-09-2019
Willy Barton / Shutterstock.com
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline (GSK) has willfully infringed one of its patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GlaxosmithKline, Vectura, US District Court for the District of Delaware, patent infringement, Ellipta